id: NEW:dexmedetomidine_adjunctive_therapy_to_NEW:tracheal_intubation_rate
name: Dexmedetomidine Adjunctive Therapy â†’ Tracheal Intubation Rate
from_node:
  node_id: NEW:dexmedetomidine_adjunctive_therapy
  node_name: Dexmedetomidine Adjunctive Therapy
to_node:
  node_id: NEW:tracheal_intubation_rate
  node_name: Tracheal Intubation Rate
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Dexmedetomidine is administered as adjunctive therapy alongside standard
  benzodiazepine treatment for alcohol withdrawal syndrome (AWS)'
- 'Step 2: Dexmedetomidine provides sedation and controls autonomic hyperactivity
  without causing respiratory depression, unlike benzodiazepines'
- 'Step 3: The absence of respiratory depression theoretically reduces the need for
  airway protection and mechanical ventilation'
- 'Step 4: Reduced respiratory compromise may decrease the clinical indication for
  tracheal intubation in AWS patients'
evidence:
  quality_rating: A
  n_studies: 8
  primary_citation: 'Marco Fiore et al. 2024. Dexmedetomidine as Adjunctive Therapy
    for the Treatment of Alcohol Withdrawal Syndrome: A Systematic Review and Meta-Analysis.
    Pharmaceuticals (Basel, Switzerland).'
  supporting_citations: []
description: 'This systematic review and meta-analysis of 8 studies examined whether
  dexmedetomidine as adjunctive therapy reduces tracheal intubation rates in patients
  with alcohol withdrawal syndrome. The meta-analysis found a non-statistically significant
  trend toward reduced intubation (RR: 0.57, 95% CI: 0.25-1.3), suggesting dexmedetomidine
  may reduce intubation risk by approximately 43%, though the confidence interval
  includes null effect. The theoretical mechanism is that dexmedetomidine provides
  sedation without respiratory depression, potentially reducing the need for airway
  protection.'
last_updated: '2025-12-02'
extraction_method: consolidated_batch_v3
quantitative_effects:
  effect_size:
    value: 0.57
    type: relative_risk
    ci_lower: 0.25
    ci_upper: 1.3
  p_value: null
  sample_size: null
moderators:
- name: AWS severity
  direction: strengthens
  strength: moderate
  description: Dexmedetomidine is typically used in cases where benzodiazepines alone
    are inadequate in controlling persistent autonomic hyperactivity or anxiety
